Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178672 | 0.84 | APP (0.38) | HTTALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL4069704 | 0.84 | PARP1 (0.37) | LMNAPARP1CDK9DYRK1ADYRK2 | |
| SCHEMBL30376225 | 0.81 | HTT (0.64) | HTTALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL13081604 | 0.81 | TYMS (0.40) | HTTALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL1069686 | 0.81 | HTT (0.39) | HTTALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL21500701 | 0.81 | HTT (0.64) | HTTALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL405341 | 0.79 | KDM4E (0.44) | HTTALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL30013869 | 0.79 | KDM4E (0.44) | HTTALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL7438098 | 0.78 | CDK9 (0.36) | MAPTPARP1CDK9DYRK1ADYRK2 | |
| SCHEMBL7436724 | 0.77 | CDK2 (0.41) | ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024082872-A1 | PAK4 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都海博为药业有限公司 | 2024-04-25 | — | — | WO | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-115925694-A | PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115943144-A | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114075175-A | Compound serving as PAK4 kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2021-03-25 | — | — | US | disclosed |
| EP-3658586-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2020-06-03 | — | — | EP | disclosed |
| CN-111108127-A | Compounds that specifically bind CD38 for use in the treatment of neurodegenerative and inflammatory diseases | ENCEFA公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2008086462-A2 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-1913016-A1 | MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| WO-2007016441-A1 | MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20040167121-A1 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
| WO-2004037814-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1230225-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032632-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | CD38, TRPC1, TRPC4 | HTT 458/4885ALDH1A1 2501/4885KDM4E 3720/4885 |
| US-20040167121-A1 | Indazolinone compositions useful as kinase inhibitors | LCK, CDK2, CILK1 | HTT 4343/4885ALDH1A1 4153/4885KDM4E 1499/4885 |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | HTT 3152/4885ALDH1A1 927/4885KDM4E 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.